Exploring CAR T-cell therapy for aggressive follicular lymphoma
CAR T-cell therapy is an effective treatment for aggressive subtypes of follicular lymphoma, according to a clinical trial published in Nature Medicine.
Jul 18, 2024
0
52
Hemic and Lymphatic Diseases: News and Research on Lymphoma, Non-Hodgkin
MeSH tree: C15.604.515.569.480
Personalized simulations predict patient outcomes for blood cancer treatment in breakthrough study
A study led by researchers at Brighton and Sussex Medical School (BSMS) has unveiled an approach to predicting the effectiveness of treatments for patients with diffuse large B-cell lymphoma (DLBCL), a common form of blood ...
Jul 15, 2024
0
35
Trial of cell-based therapy for high-risk lymphoma leads to FDA breakthrough designation
CAR-T cell therapy, which targets a specific protein on the surface of cancer cells, causes tumors to shrink or disappear in about half of patients with large B-cell lymphoma who haven't experienced improvement with chemotherapy ...
Jul 10, 2024
0
36
Lymphoma patients at high risk of infections after diagnosis
Every year, around 100 people are affected by mantle cell lymphoma. A study at Uppsala University shows that these patients are more vulnerable to other diseases and that the risk of infection for this type of patient should ...
Jul 8, 2024
0
31
Glofitamab + GemOx superior to rituximab + GemOx for lymphoma
Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a study presented at the annual hybrid congress ...
Jun 26, 2024
0
36
Reduced infections seen in CLL and NHL patients undergoing immunoglobulin testing and replacement therapy
Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience severe infections compared with those who didn't, according ...
Jun 21, 2024
0
34
Combination targeted treatment produces lasting remissions in people with resistant aggressive B-cell lymphoma
Researchers at the National Institutes of Health (NIH) have developed a non-chemotherapy treatment regimen that is achieving full remissions for some people with aggressive B-cell lymphoma that has come back or is no longer ...
Jun 19, 2024
0
66
Researchers uncover mechanism that fuels growth of aggressive B-cell lymphoma
Researchers from the University of Helsinki and HUS investigated the effects of recurring mutations in the KLHL6 gene in diffuse large B-cell lymphoma, the most common cancer of the lymphatic system.
Jun 18, 2024
0
30
Risk of secondary cancers after CAR-T cell therapy low, according to large study
A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR-T cell therapy—a cell-based cancer treatment that exploded on the scene in 2017 as a treatment for intractable ...
Jun 12, 2024
0
57
Research pair finds Gen X people more susceptible to many types of cancers than prior generations
A pair of biostatisticians at the U.S. National Cancer Institute, has found that members of Generation X are more susceptible to many kinds of cancers than their parents or grandparents were. In their study, published in ...
